November 8, 2022

To,
The Surveillance Department,
National Stock Exchange of India Limited,
Mumbai.

Kind Attention: Mr. Binoy Yohannan

Sub: Clarification/Confirmation on news item appearing in "Media/Publication".

Dear Sir,

We refer to your letter bearing Ref No. NSE/CM/Surveillance/12444 dated November 3, 2022.

We wish to state that on September 29, 2022, we had communicated to your Exchange (copy enclosed), about receipt of warning letter from the U.S. FDA, for the Company's Tarapur, Maharashtra facility.

As requested, we offer our comments as under on the news item: -

a) In our communication dated September 29, 2022, we have informed your Exchange that the Company received a warning letter from the U.S. FDA for the Company's Tarapur, Maharashtra (India) facility and that the U.S. FDA had inspected this site from March 22, 2022 to April 4, 2022.

b) Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on September 29, 2022, the Company intimated the Exchange about the receipt of warning letter from the U.S. FDA.

c) The Company informed the Exchange that it does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility and that we are committed to addressing the concerns raised by the U.S. FDA and will work with them to resolve these issues at the earliest.

We wish to add that the Company upholds quality and compliance issues with utmost importance and remains committed to be compliant with CGMP quality standards across all our facilities.

Thanking you,

For LUPIN LIMITED

LUPIN LIMITED INDIA MUMBAI

R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)

Encl-: a/a

September 29, 2022

BSE Limited
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051

Dear Sir/Madam,

Re: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).

Subject: Communication from U.S. FDA regarding the Company's Tarapur, Maharashtra (India) facility.

We wish to inform you that the Company has received a warning letter from the U.S. FDA for the Company's Tarapur, Maharashtra (India) facility. The U.S. FDA had inspected the Lupin Tarapur site from March 22, 2022 to April 4, 2022.

The Company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility.

We are committed to addressing the concerns raised by the U.S. FDA and will work with the U.S. FDA to resolve these issues at the earliest. We uphold quality and compliance issues with utmost importance and remain committed to be compliant with CGMP quality standards across all our facilities.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

Rajvardhan Vishnu Satam

Digitally signed by Rajvardhan Vishnu Satam
DN: c=IN, st=Maharashtra, 2.5.4.20=c19d8ef961d9fa59e973a093a4d39240b2533eb2f496ea7e2ab
cf747200f53778cf, postalCode=400104, street=2404,SEJAL TOWER,SEJAL PARK LINK ROAD,GOREGAON WEST,Mumbai,Motilal Nagar,Borivali,Mumbai Suburban, pseudonym=9a4b7cd2190aa516ad56e6d651dcbbe5b, title=0191, serialNumber=dfbeba60a88c796663c738ea25bfa0b475d195f726cdb67a2ff09c624277 1b2a, o=Personal, cn=Rajvardhan Vishnu Satam
Date: 2022.09.29 10:13:40 +05'30'

R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)